Last edition
News about "Dr Richard Hatchett"
SK Bioscience Begins Study of Sarbecovirus Vaccine
SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.
Dr Richard Hatchett | 30/01/2026 | By News Bureau
SK bioscience, MSD and Hilleman Advance Ebola Vaccine with CEPI Funding
he collaboration will receive up to USD 30 million in CEPI funding to support development of MSD’s Zaire ebolavirus vaccine, with a focus on improving manufacturing efficiency, enhancing thermostability and expanding affordable vaccine access in low- and middle-income countries.
Dr Richard Hatchett | 23/01/2026 | By News Bureau
Serum Institute to Produce 100,000 Doses of Oxford Rift Valley Fever Vaccine
Serum Institute of India will produce up to 100,000 doses of an investigational Rift Valley fever vaccine developed by the University of Oxford, as the viral disease continues to affect parts of West Africa. The doses may be used for testing and future outbreak response, under an agreement supported by CEPI.
Dr Richard Hatchett | 17/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy